Viridian Therapeutics, Inc.\DE (VRDN) Preferred Stock Liabilities (2015 - 2016)
Viridian Therapeutics, Inc.\DE (VRDN) posted quarterly Preferred Stock Liabilities of $77.0 million for Q4 2016, up 26.5% year-over-year from $60.8 million in Q1 2016, and up 26.5% quarter-over-quarter from $60.8 million in Q4 2015.
Powered by 
Analysis
Viridian Therapeutics, Inc.\DE (VRDN) Preferred Stock Liabilities (2015 - 2016) Analysis & Trends
Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $77.0 million for Q4 2016.
- In Q4 2016, Preferred Stock Liabilities rose 26.5% year-over-year to $77.0 million; the TTM figure through Dec 2016 stood at $77.0 million (up 26.5% YoY), while the FY2016 annual figure was $77.0 million, up 26.5% from the prior year.
- Preferred Stock Liabilities for Q4 2016 stood at $77.0 million, up from $60.8 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $77.0 million in Q4 2016, with the low at $60.8 million in Q4 2015.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Viridian Therapeutics, Inc.\DE | 2.42 Bn | 2.42 Bn | - | - |